Analyst consensus shifted upward for biopharma names and lower for materials and chemicals on August 1.
Regeneron Pharmaceuticals saw its average analyst target price nudge up to $832.43. The $73.8 billion biotech carries just 3.5% short interest. 17 analysts maintain buy ratings. The positive revision follows ongoing strength in the company's drug portfolio.
Biogen also received a target lift, with consensus edging to $234.35. 23 analysts hold buy ratings on the stock. The biopharma sector saw broad upward revisions today.
West Pharmaceutical Services gained fresh analyst momentum. Target prices moved to $404.73. 14 of 17 covering analysts rate it a buy.
On the downside, Martin Marietta Materials saw its consensus target trimmed to $671.61. The aggregates giant has a $32.4 billion market cap. Only 13 buy ratings remain versus 8 holds.
Linde also saw a modest target cut to $545.54. The industrial gas leader still commands 20 buy ratings from analysts.
Eaton Corporation received a fresh new recommendation with a consensus target of $452.95 from 16 analysts. No prior consensus existed for comparison.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
